Showing results (671-680 of 1,995) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|December 1, 2009
An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive studyDaniel H Lachance, Vanda A Lennon, Sean J Pittock, et al.
The Lancet. Neurology|April 17, 2018
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learnedEugene O Major, Tarek A Yousry, David B Clifford
The Lancet. Neurology|May 1, 2017
Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional studyClifford R Jack, Heather J Wiste, Stephen D Weigand, et al.
The Lancet. Neurology|May 3, 2017
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trialEnrico Bertini, Eric Dessaud, Eugenio Mercuri, et al.
The Lancet. Neurology|July 8, 2017
Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control studyMorten Gersel Stokholm, Alex Iranzo, Karen Østergaard, et al.
The Lancet. Neurology|June 28, 2017
Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort studyJoukje van der Naalt, Marieke E Timmerman, Myrthe E de Koning, et al.
The Lancet. Neurology|June 28, 2017
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approachesAdam L Boxer, Jin-Tai Yu, Lawrence I Golbe, et al.
The Lancet. Neurology|February 2, 2010
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal studySamantha Jilek, Emilie Jaquiéry, Hans H Hirsch, et al.
The Lancet. Neurology|March 2, 2010
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O Rinne, David J Brooks, Martin N Rossor, et al.
The Lancet. Neurology|June 6, 2018
In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control studyKaroline Knudsen, Tatyana D Fedorova, Allan K Hansen, et al.
Pageof 200